Back to search
FDAFDA · Food and drugs·Recall number Z-1240-2016

Siemens ADVIA Centaur Enhance Estradiol Test Code eE2 Catalog Number: 10490889, 10491445, 10697757 Product Usage: For in vitro diagnostic use in the quantitative determination of estradiol in human serum and plasma (heparinized and EDTA) using the ADVIA Centaur®, ADVIA Centaur XP, ADVIA Centaur XPT and ADVIA Centaur CP systems.

Published March 30, 2016 · Recall initiated: January 13, 2016

Summary

FDA records medical device Class II recall Z-1240-2016, published March 30, 2016 and initiated January 13, 2016. Recalling firm: Siemens Healthcare Diagnostics, Inc; Status: Terminated; Reported quantity: 33604 units; Lot: All lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc
Distributor
Worldwide Distribution  US Nationwide , AR, AU, AU, BD, BO, BR, CA, CH, CL, CN, CO, DO, EC, EG, HK, ID, IE, IL, IN, JP, KR, LK, LY, MX, MY, NI, NP, NZ, PE, PH, PY, SA, SG, SV, TH, TW, UY, VE, VN, and ZA.
Lot
All lots
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Siemens ADVIA Centaur Enhance Estradiol Test Code eE2 Catalog Number: 10490889, 10491445, 10697757 Product Usage: For in vitro diagnostic use in the quantitative determination of estradiol in human serum and plasma (heparinized and EDTA) using the ADVIA Centaur®, ADVIA Centaur XP, ADVIA Centaur XPT and ADVIA Centaur CP systems. recalled?

Yes. FDA published recall Z-1240-2016 on March 30, 2016. Reported hazard: The drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter